Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors.
We have studied relative efficacies of NR1 agonists glycine and d-cycloserine (DCS), and found efficacy to be dependent on the NR2 subunit. DCS shows partial agonism at NR1/NR2B but has higher relative efficacy than glycine at NR1/NR2C receptor. Molecular dynamics (MD) simulations of the NR1/NR2B and NR1/NR2C agonist binding domain dimer suggest only subtle differences in the interactions of DCS with NR1 binding site residues relative to glycine. The most pronounced differences were observed in the NR1/NR2C simulation between the orientation of helices F and G of the NR1 subunit. Interestingly, Helix F was previously proposed to influence receptor gating and to adopt an orientation depending on agonist efficacy. MD simulations and site-directed mutagenesis further suggest a role for residues at the agonist binding domain dimer interface in regulating DCS efficacy. To relate the structural rearrangements to receptor gating, we recorded single-channel currents from outside-out patches containing a single active NR1/NR2C receptor. DCS increased the mean open time and open probability of NR1/NR2C receptors compared with glycine. Maximum likelihood fitting of a gating model for NR1/NR2C receptor activation to the single-channel data suggests that DCS specifically accelerates the rate constant governing a fast gating step and reduces the closing rate. These changes appear to reflect a decreased activation energy for a pregating step and increased stability of the open states. We suggest that the higher efficacy of DCS at NR1/NR2C receptors involves structural rearrangements at the dimer interface and an effect on NR1/NR2C receptor pregating conformational changes.
Dravid
Shashank M
SM
Department of Pharmacology, Creighton University, Omaha, Nebraska 68178, USA. ShashankDravid@creighton.edu
Burger
Pieter B
PB
Prakash
Anand
A
Geballe
Matthew T
MT
Yadav
Roopali
R
Le
Phuong
P
Vellano
Kimberly
K
Snyder
James P
JP
Traynelis
Stephen F
SF
D000818:Animals; D000904:Antibiotics, Antitubercular / Q000494:pharmacology*; D001703:Biophysics; D002461:Cell Line, Transformed; D003198:Computer Simulation; D003523:Cycloserine / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation / Q000379:methods; D005260:Female; D005998:Glycine / Q000494:pharmacology; D006801:Humans; D015640:Ion Channel Gating / Q000187:drug effects* / Q000235:genetics; D008564:Membrane Potentials / Q000187:drug effects* / Q000235:genetics*; D008845:Microinjections / Q000379:methods; D008958:Models, Molecular; D056004:Molecular Dynamics Simulation; D016296:Mutagenesis / Q000235:genetics; D009865:Oocytes; D018408:Patch-Clamp Techniques / Q000379:methods; D054730:Protein Interaction Domains and Motifs / Q000187:drug effects / Q000235:genetics; D016194:Receptors, N-Methyl-D-Aspartate / Q000235:genetics / Q000378:metabolism*; D014982:Xenopus laevis
D000904:Antibiotics, Antitubercular; C409466:NR1 NMDA receptor; C432823:NR2C NMDA receptor; D016194:Receptors, N-Methyl-D-Aspartate; D003523:Cycloserine; D005998:Glycine